Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 128 Cr.
- Current Price ₹ 240
- High / Low ₹ 316 / 175
- Stock P/E 20.3
- Book Value ₹ 55.8
- Dividend Yield 0.00 %
- ROCE 35.2 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 136 days to 85.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.72%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 17.80 | 61.73 | |
| 15.54 | 52.85 | |
| Operating Profit | 2.26 | 8.88 |
| OPM % | 12.70% | 14.39% |
| 0.03 | 0.08 | |
| Interest | 0.09 | 0.21 |
| Depreciation | 0.01 | 0.02 |
| Profit before tax | 2.19 | 8.73 |
| Tax % | 27.85% | 27.49% |
| 1.59 | 6.33 | |
| EPS in Rs | 3.24 | 12.74 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 247% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 298% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 4.90 | 4.97 |
| Reserves | 13.32 | 22.77 |
| 1.60 | 3.26 | |
| 0.96 | 4.57 | |
| Total Liabilities | 20.78 | 35.57 |
| 0.05 | 1.65 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.42 | 0.43 |
| 20.31 | 33.49 | |
| Total Assets | 20.78 | 35.57 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.87 | 1.21 | |
| -0.52 | -1.56 | |
| 13.13 | 2.86 | |
| Net Cash Flow | 8.74 | 2.50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 66.03 | 86.09 |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 66.03 | 86.09 |
| Working Capital Days | 186.81 | 85.56 |
| ROCE % | 35.18% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 1d
-
Disclosure Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 - Alteration In Memorandum Of Association ("MOA") Of Royal Sense Limited.
30 Sep - Special resolution at AGM (30 Sep 2025) approved alteration to Memorandum of Association; revised MOA attached.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Sep
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep - 29 Sep 2025 AGM approved FY2024-25 financials, re‑appointed Vikas, approved RPT limits and MOA alteration.
- Closure of Trading Window 26 Sep
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.